<DOC>
	<DOCNO>NCT00436800</DOCNO>
	<brief_summary>Primary objective : To evaluate response rate biweekly gemcitabine oxaliplatin ( GEMOX regimen ) first line treatment metastatic recurrent nasopharyngeal carcinoma . Secondary objective : To assess toxicity , duration response , time progression , progression-free survival , overall survival cancer-related symptom first line treatment patient metastatic recurrent NPC .</brief_summary>
	<brief_title>Gemcitabine Oxaliplatin ( GEMOX ) First Line Metastatic Recurrent Nasopharyngeal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Patients histologically cytologically proven nasopharyngeal carcinoma ( NPC ) metastatic recurrent disease amenable potentially curative surgery radiotherapy . They must prior chemotherapy treatment metastatic recurrent disease . Prior neoadjuvant , adjuvant concurrent chemotherapy allow long minimum period 6 week elapse since last day treatment . This include use carboplatin cisplatin . Patients must least one unidimensional measurable lesion ( accord RECIST criterion ) Prior RT surgery target lesion ( ) allow long documented disease progression within RT/ surgical field , minimum period 6 week elapse since last day treatment . Eastern Cooperative Oncology Group performance status 02 No serious , uncontrolled medical condition may aggravate treatment . No malignancy ( ) , except completely excise basal squamous cell carcinoma skin , completely treat carcinomainsitu cervix . Adequate hematological function : absolute granulocyte count &gt; 1.5 x 10^9/L , platelet count &gt; 100 x 10^9/L Adequate renal hepatic function : ·serum creatinine &lt; 1.25 x upper normal limit ( UNL ) calculate creatinine clearance &gt; 50 mL/min·serum bilirubin &lt; 2 x UNL Aspartate aminotransferase/Alanine aminotransferase &lt; 3 x UNL Prior treatment Oxaliplatin Gemcitabine . Patients persistent grade 2 sensory and/or motor neuropathy , ototoxicity result prior cisplatin/ carboplatin . Active past history central nervous system metastasis primary tumor Potentially lifethreatening infection Patients use investigational drug treatment month prior inclusion . Pregnancy exercise appropriate birth control course study . Breastfeeding woman The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>